Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III trial investigating the efficacy of an encapsulated cell therapy product [NovaCaps] versus gemcitabine for advanced, inoperable pancreatic cancer

Next Previous
Trial Profile

Phase III trial investigating the efficacy of an encapsulated cell therapy product [NovaCaps] versus gemcitabine for advanced, inoperable pancreatic cancer

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 24 Oct 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Microencapsulated CYP2B1-expressing cells+ifosfamide PharmaCyte Biotech (Primary) ; Gemcitabine; Ifosfamide
  • Indications Pancreatic cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors PharmaCyte Biotech

    • Most Recent Events

    • 24 Oct 2016 According to a PharmaCyte Biotech media release, Manuel Hidalgo, MD, PhD has agreed to serve as the Principal Investigator for this trial.
    • 04 Nov 2013 Cloning of the cancer-drug-activating cells required for phase 3 clinical trials has begun at Inno Biologics, according to a Nuvilex media release.
    • 19 Sep 2013 Inno Biologics will generate cell clones for production of microencapsulated CYP-2B1-expressing cells for this trial, and Fisher BioServices will store them, according to a Nuvilex media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top